Solasia Pharma K K : Partner, Isofol Receives FDA Fast Track Designation for arfolitixorin (SP-05) in Advanced Colorectal Cancer

To: All Concerned Parties	November 24, 2021
Company Name: Solasia Pharma K.K.
Representative:	Yoshihiro Arai, President & CEO
(Code number:	4597, TSE Mothers Section)
Contact:	Toshio Miyashita, CFO, Director
Tel:	81-3-5843-8045
URL:	https://solasia.co.jp/en/

Solasia's Partner, Isofol Receives FDA Fast Track Designation

for arfolitixorin (SP-05) in Advanced Colorectal Cancer

Isofol Medical AB (publ) (STO: ISOFOL), Solasia's partner announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the development of the drug candidate arfolitixorin (SP-05), the stabilized and biologically active pure form of folate ([6R]- MTHF), for treatment of patients with metastatic colorectal cancer (mCRC).

For more information, please refer to the Isofol´s website. Link

###